RT Journal Article
SR Electronic
T1 Global Biobank Meta-analysis Initiative: powering genetic discovery across human diseases
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.11.19.21266436
DO 10.1101/2021.11.19.21266436
A1 Zhou, Wei
A1 Kanai, Masahiro
A1 Wu, Kuan-Han H
A1 Humaira, Rasheed
A1 Tsuo, Kristin
A1 Hirbo, Jibril B
A1 Wang, Ying
A1 Bhattacharya, Arjun
A1 Zhao, Huiling
A1 Namba, Shinichi
A1 Surakka, Ida
A1 Wolford, Brooke N
A1 Faro, Valeria Lo
A1 Lopera-Maya, Esteban A
A1 Läll, Kristi
A1 Favé, Marie-Julie
A1 Chapman, Sinéad B
A1 Karjalainen, Juha
A1 Kurki, Mitja
A1 Mutaamba, Maasha
A1 Brumpton, Ben M
A1 Chavan, Sameer
A1 Chen, Tzu-Ting
A1 Daya, Michelle
A1 Ding, Yi
A1 Feng, Yen-Chen A
A1 Gignoux, Christopher R
A1 Graham, Sarah E
A1 Hornsby, Whitney E
A1 Ingold, Nathan
A1 Johnson, Ruth
A1 Laisk, Triin
A1 Lin, Kuang
A1 Lv, Jun
A1 Millwood, Iona Y
A1 Palta, Priit
A1 Pandit, Anita
A1 Preuss, Michael
A1 Thorsteinsdottir, Unnur
A1 Uzunovic, Jasmina
A1 Zawistowski, Matthew
A1 Zhong, Xue
A1 Campbell, Archie
A1 Crooks, Kristy
A1 De Bock, Geertruida h
A1 Douville, Nicholas J
A1 Finer, Sarah
A1 Fritsche, Lars G
A1 Griffiths, Christopher J
A1 Guo, Yu
A1 Hunt, Karen A
A1 Konuma, Takahiro
A1 Marioni, Riccardo E
A1 Nomdo, Jansonius
A1 Patil, Snehal
A1 Rafaels, Nicholas
A1 Richmond, Anne
A1 Shortt, Jonathan A
A1 Straub, Peter
A1 Tao, Ran
A1 Vanderwerff, Brett
A1 Barnes, Kathleen C
A1 Boezen, Marike
A1 Chen, Zhengming
A1 Chen, Chia-Yen
A1 Cho, Judy
A1 Smith, George Davey
A1 Finucane, Hilary K
A1 Franke, Lude
A1 Gamazon, Eric
A1 Ganna, Andrea
A1 Gaunt, Tom R
A1 Ge, Tian
A1 Huang, Hailiang
A1 Huffman, Jennifer
A1 Lajonchere, Clara
A1 Law, Matthew H
A1 Li, Liming
A1 Lindgren, Cecilia M
A1 Loos, Ruth JF
A1 MacGregor, Stuart
A1 Matsuda, Koichi
A1 Olsen, Catherine M
A1 Porteous, David J
A1 Shavit, Jordan A
A1 Snieder, Harold
A1 Trembath, Richard C
A1 Vonk, Judith M
A1 Whiteman, David
A1 Wicks, Stephen J
A1 Wijmenga, Cisca
A1 Wright, John
A1 Zheng, Jie
A1 Zhou, Xiang
A1 Awadalla, Philip
A1 Boehnke, Michael
A1 Cox, Nancy J
A1 Geschwind, Daniel H
A1 Hayward, Caroline
A1 Hveem, Kristian
A1 Kenny, Eimear E
A1 Lin, Yen-Feng
A1 Mägi, Reedik
A1 Martin, Hilary C
A1 Medland, Sarah E
A1 Okada, Yukinori
A1 Palotie, Aarno V
A1 Pasaniuc, Bogdan
A1 Sanna, Serena
A1 Smoller, Jordan W
A1 Stefansson, Kari
A1 van Heel, David A
A1 Walters, Robin G
A1 Zoellner, Sebastian
A1 ,
A1 ,
A1 ,
A1 ,
A1 ,
A1 ,
A1 ,
A1 ,
A1 ,
A1 ,
A1 ,
A1 ,
A1 ,
A1 ,
A1 ,
A1 ,
A1 ,
A1 ,
A1 ,
A1 Martin, Alicia R
A1 Willer, Cristen J
A1 Daly, Mark J
A1 Neale, Benjamin M
YR 2021
UL http://medrxiv.org/content/early/2021/11/21/2021.11.19.21266436.abstract
AB Biobanks are being established across the world to understand the genetic, environmental, and epidemiological basis of human diseases with the goal of better prevention and treatments. Genome-wide association studies (GWAS) have been very successful at mapping genomic loci for a wide range of human diseases and traits, but in general, lack appropriate representation of diverse ancestries - with most biobanks and preceding GWAS studies composed of individuals of European ancestries. Here, we introduce the Global Biobank Meta-analysis Initiative (GBMI) -- a collaborative network of 19 biobanks from 4 continents representing more than 2.1 million consented individuals with genetic data linked to electronic health records. GBMI meta-analyzes summary statistics from GWAS generated using harmonized genotypes and phenotypes from member biobanks. GBMI brings together results from GWAS analysis across 6 main ancestry groups: approximately 33,000 of African ancestry either from Africa or from admixed-ancestry diaspora (AFR), 18,000 admixed American (AMR), 31,000 Central and South Asian (CSA), 341,000 East Asian (EAS), 1.4 million European (EUR), and 1,600 Middle Eastern (MID) individuals. In this flagship project, we generated GWASs from across 14 exemplar diseases and endpoints, including both common and less prevalent diseases that were previously understudied. Using the genetic association results, we validate that GWASs conducted in biobanks worldwide can be successfully integrated despite heterogeneity in case definitions, recruitment strategies, and baseline characteristics between biobanks. We demonstrate the value of this collaborative effort to improve GWAS power for diseases, increase representation, benefit understudied diseases, and improve risk prediction while also enabling the nomination of disease genes and drug candidates by incorporating gene and protein expression data and providing insight into the underlying biology of the studied traits.Competing Interest StatementM.J.D. is a founder of Maze Therapeutics. B.M.N. is a member of the scientific advisory board at Deep Genomics and consultant for Camp4 Therapeutics, Takeda Pharmaceutical, and Biogen. The spouse of C.J.W works at Regeneron Pharmaceuticals. C.Y.C. is employed by Biogen. C.R.G. owns stock in 23andMe, Inc. T.R.G. has received research funding from various pharmaceutical companies to support the application of Mendelian randomization to drug target prioritization. E.E.K. has received speaker fees from Regeneron, Illumina, and 23&Me, and is a member of the advisory board for Galateo Bio. R.E.M. has received speaker fees from Illumina and is a scientific advisor to the Epigenetic Clock Development Foundation. G.D.S has received research funding from various pharmaceutical companies to support the application of Mendelian randomization to drug target prioritization. K.S. and U.T. are employed by deCODE Genetics/Amgen inc. J.Z. has received research funding from various pharmaceutical companies to support the application of Mendelian randomization to drug target prioritization.Funding StatementPlease refer to Supplementary Note for information regarding individual studies involved in the Global Biobank Meta-analysis Initiative.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Please refer to Supplementary Note for information regarding individual studies involved in the Global Biobank Meta-analysis Initiative.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe all-biobank meta-analysis results and plots for the 14 endpoints (including both ancestry-specific and cross-ancestry meta-analyses and sex stratified meta-analyses) are available for downloading at https://www.globalbiobankmeta.org/resources and browsed at the PheWeb Browser http://results.globalbiobankmeta.org. Custom scripts used for quality control, meta-analysis and summary of results are available at https://github.com/globalbiobankmeta. The optimized trans-ancestry and single-ancestry polygenic score weights will be deposited within the PGS Catalog (https://www.pgscatalog.org/). https://www.globalbiobankmeta.org/resources